

# Material Information (3176 MEDIGEN?????)

SEQ_NO	3	Date of announcement	2024/05/28	Time of announcement	17:19:39
Subject	Approval of the Proposal to Lift the Non-Compete Restrictions on Newly Appointed Directors at 2024 Shareholders' Meeting.				
Date of events	2024/05/28	To which item it meets	paragraph 21		
Statement	<div>1.Date of the shareholders' meeting resolution:2024/05/28</div> <div>2.Name and title of the managerial officer with permission to engage in competitive conduct: Chairman: Shi-Chung Chang Independent Director: Sheue -Rong Lin</div> <div>3.Items of competitive conduct in which the officer is permitted to engage: (1)Director: Shi-Chung Chang Director, U-GEN BIOTECHNOLOGY INC. Chairman, TBG Biotechnology Corp. Director, TBG Diagnostics Ltd. Chairman, Medigen Biotechnology Corp. (Beijing) Chairman, Medigen Biotechnology Corp. (Xiamen) Director, TBG Biotechnology (Xiamen) Inc. Chairman, Yingxin Investment Corp. Representative of corporate director, Winston Medical Supply Co., Ltd. Chairman, UMO International Co., Ltd. Chairman, Shiny Lily Co., Ltd. Director, MVC BioPharma Ltd. Director, TDL Holding Co. (2)Independent Director: Sheue -Rong Lin CEO, Liver Disease Prevention &amp; Treatment Research Foundation</div> <div>4.Period of permission to engage in the competitive conduct:During Their Term of Office as Directors.</div> <div>5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):The total number of voting rights represented by shareholders present at the time of voting was 96,085,916. The voting results for this proposal were: (1) Votes in favor: 94,117,299 (2) Votes against: 112,028 (3) Abstentions/Non-voting:1,856,589 (4) Invalid votes: 0 The affirmative votes for this proposal constitute 99.40% of the total voting rights, exceeding two-thirds of the total voting rights present. Therefore, the proposal is approved.</div> <div>6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter "N/A" below): Director Shi-Chung Chang</div> <div>7.Company name of the mainland China enterprise and the officer's position in the enterprise: Chairman, Medigen Biotechnology Corp. (Beijing) Chairman, Medigen Biotechnology Corp. (Xiamen) Director, TBG Biotechnology (Xiamen) Inc.</div> <div>8.Address of the mainland China enterprise: (1)Medigen Biotechnology Corp. (Beijing): 3F, No. 101, West Sihuan South Road, Fengtai District, Beijing, People's Republic of China. (2)Medigen Biotechnology Corp. (Xiamen): 4F-2, Building 3, No. 2004, Wengjiao West Road, Haigang District, Xiamen, People's Republic of China. (3)TBG Biotechnology (Xiamen) Inc.: 4F-1, Building 3, No. 2004, Wengjiao West Road, Haigang District, Xiamen, People's Republic of China.</div> <div>9.Operations of the mainland China enterprise: (1)Medigen Biotechnology Corp. (Beijing): Investment Operations. (2)Medigen Biotechnology Corp. (Xiamen): New Drug Research and Clinical Development, Production Technology Support, Related Technical Consultation, and After-Sales Service. (3)TBG Biotechnology(Xiamen) Inc.: Research and Development of Clinical Diagnostic Reagents, Production Preparation, Sales of Reagents and Related Equipment, Technical Consultation, and After-Sales Service.</div> <div>10.Impact on the company's finance and business:Companies in which the company holds direct or indirect investments using the equity method.</div> <div>11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:None</div> <div>12.Any other matters that need to be specified:None</div>				